The panel takes places at OIS@ASRS at the Ritz Carlton in Chicago on July 25, 2019.
Presented By:
Glenn Yiu, MD, PhD, Associate Professor - University of California, Davis | DOWNLOAD
Panel Discussion
Participants:
Thomas Ciulla, MD, MBA, Chief Medical Officer - Clearside Biomedical
Mehdi Gasmi, PhD,President & Chief Scientific Officer - Adverum Biotechnologies
Mark Humayun, MD, PhD, Professor of Ophthalmology - University of Southern California
Steve Pakola, MD, SVP & Chief Medical Officer - REGENXBIO
Glenn Yiu, MD, PhD, Associate Professor - University of California, Davis
Moderated By:
John Pollack, MD, Partner - Illinois Retina Associates
WEBSITE
FOLLOW Ophthalmology Innovation Summit On Social Media:
► Facebook:
► Twitter:
JOIN Our Group For Ophthalmology Innovation & Investment On LinkedIn
SUBSCRIBE To Our Weekly OIS Newsletter
VIEW Our Past Ophthalmology Event Conferences:
REGISTER For Our Next Conference:
#OIS #Ophthalmology #Healthcare
_________________________________________________________________
About OIS
Ophthalmology Innovation Summit, or OIS for short, facilitates meaningful interactions and the exchange of information between clinical, capital, and corporate leaders to accelerate the development and commercialization of novel therapies to address unmet needs.
The Ophthalmology Innovation Summit programs are presented annually by Healthegy, Inc. as affiliate meetings with American Academy of Ophthalmology (AAO), American Society of Cataract and Refractive Surgery (ASCRS), Southeastern Congress of Optometry (SECO), and American Society of Retina Specialists (ASRS).
____________________________________________________________________
Healthegy also is the producer of Aesthetics Innovation Summit (AIS), which unites the clinical, corporate and capital leaders to facilitate the exchange of insights on emerging trends while showcasing exciting new drugs, devices, and technologies for the aesthetics market which is projected to double by 2025.
► Website:
► Facebook:
► Instagram:
► Twitter:
► Healthegy Website:
0 Comments